Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot Study

Table 1 Baseline summary by treatment

Demographic	Anti-VEGF		Sirolimus
	N = 20		N = 20
	Mean	SD	Mean	SD
Age at baseline (years)	79.24	8.86	84.46	5.76
Time with Wet AMD (months)	76.95	55.83	54.20	40.43
Total previous intravitreal anti-VEGF injections	36.95	21.87	29.45	22.03
Baseline visual acuity (ETDRS letters)	53.90	12.87	47.10	16.29
Baseline central subfield thickness (µm)	426.90	115.84	492.80	131.14
Baseline choroidal neovascularization (mm²)	4.23	3.22	6.55	4.43
Baseline central macular thickness (µm)	362.04	176.21	392.26	200.50

The baseline summary information summarizes the two study populations at their entry into the study. There was no statistical significance shown between our two study groups

ISSN: 2056-9920